Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

Cancer Biology and Medicine

Volumn 13, Issue 1, 2016, Pages 77-86

  Desai, Arpita ^a   Menon, Smitha P ^b   Dy, Grace K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Fibroblast growth factor receptor (FGFR); MEK; Non small cell lung cance (NSCLC); RAF; RAS; Receptor tyrosine kinases (RTK)

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFICACY; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

EID: 84969188079     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.28092/j.issn.2095-3941.2016.0008     Document Type: Review

References (68)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-86.
2. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998-2006.
3. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013; 19: 2584-91.
4. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1.
5. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503: 548-51.
6. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007; 67: 4933-9.
7. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebocontrolled, phase 2 study. Lancet Oncol. 2013; 14: 38-47.
8. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012; 483: 613-7.
9. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015; 5: 860-77.
10. Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 2013; 3: 444-57.
11. Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, et al, Phase 2 study of Defactinib, VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). World Conference on Lung Cancer. 2015: Denver, Colorado.
12. Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 2012; 11: 2633-43.
13. Cantwell-Dorris ER, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10: 385-94.
14. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with nonsmall- cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29: 3574-9.
15. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011; 29: 2046-51.
16. Planchard D, Kim TM, Mazières J, Quoix E, Riely GJ, Barlesi F, et al. Dabrafenib in patients with BRAF V600E- mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, Phase 2 trial (BRF113928). Ann Oncol; 2014: 25 (suppl 5): 1-41.
17. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015; 373: 726-36.
18. Planchard D, Groen HJM, Kim TM, Rigas JR, Souquet PJ, Baik CS, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2015; 33 (suppl 5); abstr 8006.
19. Holderfield M, Deuker MM, Mccormick F, Mcmahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014; 14: 455-67.
20. Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer. 2013; 82: 365-7.
21. Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, et al. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol. 2013; 31: e324-6.
22. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012; 2: 791-7.
23. Bowyer SE, Rao AD, Lyle M, Sandhu S, Long GV, Mcarthur GA, et al. Activity of trametinib in K601E and L597Q BRAF mutationpositive metastatic melanoma. Melanoma Res. 2014; 24: 504-8.
24. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012; 4: 136ra70.
25. Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, et al. Oncogenic BRaf deletions that function as homodimers and are sensitive to inhibition by Raf dimer inhibitor LY3009120. Cancer Discov. 2016 Jan 5. [Epub ahead of print]
26. Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, et al. Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep. 2015;5:9755.
27. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014; 20: 3087-93.
28. Klempner SJ, Bordoni R, Gowen K, Kaplan H, Stephens PJ, Ou SH, et al. Identification of BRAF kinase domain duplications across multiple tumor types and response to RAF inhibitor therapy. JAMA Oncol. 2016; 2: 272-4.
29. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014; 124: 1582-6.
30. Marks JL, Gong Y, Chitale D, Golas B, Mclellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008; 68: 5524-8.
31. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 2015; 21: 1935-43.
32. Mazzone M, Comoglio PM. The Met pathway: master Switch and drug target in cancer progression. FASEB J. 2006; 20: 1611-21.
33. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43.
34. Gouji T, Takashi S, Mitsuhiro T, Yukito I. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the Met gene a key factor? J Thorac Oncol. 2014; 9: e27-8.
35. Camidge DR, Ou SHI, Shapiro G, Otterson GA, Villaruz LC, Villalona-Calero MA, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32 (suppl 5): abstr 8001.
36. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of Met via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to Met inhibitors. Cancer Discov. 2015; 5: 850-9.
37. Liu XE, Jia YX, Shen YF, Chen JA, Cheng HY, Koul S, et al. Detection of frequent Met Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition J Clin Oncol. 2015. 33(15_suppl): 8020.
38. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014; 5: 4846.
39. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-29.
40. Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013; 11: 759-67.
41. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010; 2: 62ra93.
42. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20.
43. Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2014; 4: 246-57.
44. Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013; 73: 5195-205.
45. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of nonsmall cell lung cancer. Clin Cancer Res. 2014; 20: 4107-14.
46. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3: 636-47.
47. Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26: 2486-97.
48. Paik PK, Shen R, Ferry D, Soria JC, Mathewson A, Kilgour E, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. J Clin Oncol. 2014; 32 (suppl 5): abstr 8035.
49. Nogova L, Sequist LV, Cassier PA, Hidalgo M, Delord JP, Schuler MH, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol. 2014; 32 (suppl 5): abstr 8034.
50. Kilgour E, Ferry D, Saggese M, Arkenau HT, Rooney C, Smith NR, et al. Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. J Clin Oncol. 2014; 32 (suppl 5): abstr 11010.
51. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010; 16: 5936-41.
52. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012; 30: 4352-9.
53. Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014; 13: 2910-8.
54. Lee JK, Kim S, Shin JY, Lee Sh. Activity of sunitinib for lung adenocarcinoma with RET rearrangement. Cancer Res. 2015; 75 (suppl 15): abstr 2416.
55. Wu HY, Yang JC. Rapid response to sunitinib in a patient with lung adenocarcinoma harboring KIF5B-RET fusion gene. J Thorac Oncol. 2015; 10: e95-6.
56. Falchook GS, Ordóñez NG, Bastida CC, Stephens PJ, Miller VA, Gaido L, et al. Effect of the RET inhibitor vandetanib in a patient with RET Fusion-Positive metastatic Non-Small-Cell lung cancer. J Clin Oncol. 2014 Nov 3. pii: JCO.2013.50.5016. [Epub ahead of print]
57. Drilon AE, Sima CS, Somwar R, Smith R, Ginsberg MS, Riely GJ, et al. Phase II study of cabozantinib for patients with advanced RETrearranged lung cancers. J Clin Oncol. 2015; 33 (15 Suppl): 8007.
58. Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat. 2008; 29: 609-16.
59. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19: 1469-72.
60. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, et al. Durable clinical response to entrectinib in NTRK1-Rearranged Non-Small cell lung cancer. J Thorac Oncol. 2015; 10: 1670-4.
61. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183-232.
62. Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00048-9. doi: 10.1016/j.jtho.2015.10.025. [Epub ahead of print]
63. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, et al. Randomized phase II multicenter trial of two schedules of lapatinib as first-or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010; 16: 1938-49.
64. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabinecisplatin with or without trastuzumab in HER2-positive non-smallcell lung cancer. Ann Oncol. 2004; 15: 19-27.
65. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31: 1997-2003.
66. De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76: 123-7.
67. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013; 8: e19-20.
68. Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O'connell J, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015; 26: 1421-7.